Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »

Abstract Number: 492 • 2017 ACR/ARHP Annual Meeting
Is Leukotoxin_A Produced By Aggregatibacter Actynomycetemcomitans Important for Initiating Autoimmune Responses Underlying Rheumatoid Arthritis?
Mikhail Volkov¹, Jacqueline Dekkers¹, Bruno G. Loos², Sergio Bizzarro², Tom W.J. Huizinga³, Helle A. Praetorius⁴, Rene E.M. Toes⁵ and Diane van der Woude¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Periodontology, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit, Amsterdam, Netherlands, ³Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁴Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In a recent publication in Science Translational Medicine, Konig et al. (2016) describe a potential explanation for the link between periodontal infection and RA.…
Abstract Number: 676 • 2017 ACR/ARHP Annual Meeting
Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases
Theodore M. Tarasow¹, Robert Gerwien¹, Jonathan Melnick¹, Scott A. Melville¹ and Chaim Putterman², ¹HealthTell, Inc., San Ramon, CA, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Diagnosis and monitoring of patients with SLE usually requires careful evaluation by a rheumatologist. However, difficulties in accurately quantifing disease and treatment response can…
Abstract Number: 830 • 2017 ACR/ARHP Annual Meeting
Performance on Quality Measures in the RISE Registry and the Merit-Based Incentive Payment System (MIPS)
Jinoos Yazdany¹, Tracy Johansson², Rachel Myslinski³ and Salahuddin Kazi⁴, ¹Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ²Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ³Governance & Ethics Specialist, Amer College of Rheumatology, Atlanta, GA, ⁴University of Texas Southwestern, Dallas, TX
Background/Purpose: Under the new Medicare Access and CHIP Reauthorization Act (MACRA), the quality of care rheumatologists provide will have financial repercussions through the Merit Based…
Abstract Number: 928 • 2017 ACR/ARHP Annual Meeting
Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool: A Study of Medical Economics
Fei Xiao¹, Rui Wu², Zhenchun Zhang³, Weiqi Min⁴, Yanchun Tang⁵, Xinwang Duan⁶, Lingfei Mo⁷, Zhaojun Guo⁸, Yanping Zhao⁹, Henglian Wu¹⁰, Xia Xu¹¹, Feng Jiang¹², Jing Yu¹³, Jianhong Qiang¹⁴, Yan Wang⁹, Ruijie Wu¹⁵, Anbing Zhang¹⁶, Limei Gu¹⁷, Hui Xiao¹, Yuhua Jia¹, Yuan Liu¹, Bing Wu¹, Chunhui Shi¹ and Fengchun Zhang¹⁸, ¹Gothic Internet Technology Corporation, Shanghai, China, ²The First Affiliated Hospital of Nanchang University, Nanchang, China, ³People's Hospital of Linyi, Shandong, Linyi, China, ⁴Heze Municiple Hospital, Heze, China, ⁵Yantai YuHuangDing Hospital, Yantai, China, ⁶Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁷The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China, ⁸The First People's Hospital of Huainan City, Huainan, China, ⁹First Affiliated Hospital of Harbin Medical University, Harbin, China, ¹⁰Dongguan Donghua Hospital, Dongguan, China, ¹¹Changhai Hospital, Shanghai, China, ¹²Huzhou Third People's Hospital, Huzhou, China, ¹³The First Hospital Affiliated with the University of Traditional Chinese Medicine in Liaoning Province, Shenyang, China, ¹⁴Yan'an People's Hospital, Yan'an, China, ¹⁵The Second Affiliated Hospital of Shanxi Medical College, Taiyuan, China, ¹⁶Xiangyang Central Hospital, Xiangyang, China, ¹⁷Central People's Hospital of Siping, Siping, China, ¹⁸Peking Union Medical College Hospital, Beijing, China
Background/Purpose: China doesn’t have efficient primary medical care and referral system. Patients can choose any hospitals or any doctors they like to seek medical care.…
Abstract Number: 991 • 2017 ACR/ARHP Annual Meeting
Publication Timeliness of the Randomized Controlled Trials of Drug Therapy for Inflammatory Arthritis
Vyjayanthi Ganga¹, Mohan Edupuganti² and Nasim A. Khan³, ¹St. Vincent Healthcare System, Little Rock, AR, ²Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, ³Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose: Timely publication of randomized controlled trials (RCTs) is crucial for their potential impact on patient care. We assessed the publication timeliness of drug therapy…
Abstract Number: 1004 • 2017 ACR/ARHP Annual Meeting
Arthritis Impact at the State and County Level — United States, 2015
Kamil E. Barbour¹, Suson Moss², Janet Croft², Jennifer M. Hootman³, Louise Murphy⁴, Kristina Theis², Yan Wang², Hua Lu², Teresa J. Brady¹ and Charles G. Helmick², ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³Centers for Disease Control and Prevention, Kennesaw, GA, ⁴Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Arthritis, a leading cause of disability, affects 54.4 million US adults. By knowing the state and county level arthritis impact, state-level public health professionals…
Abstract Number: 1084 • 2017 ACR/ARHP Annual Meeting
Emdhaq: (electronic multidimensional health assessment questionnaire) to Record and Document eRAPID3 (electronic routine assessment of patient index data3) and eFAST3 (electronic fibromyalgia assessment screening tool3) in Routine Rheumatology Care
Theodore Pincus¹, Jacquelin R. Chua², Shakeel M. Jamal², Nathaniel Cook³, Niels Steen Krogh⁴, Anne-Marie Malfait¹ and Joel A. Block², ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Infectious Disease, Rush University Medical Center, Chicago, IL, ⁴ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: RAPID3 (routine assessment of patient index data) on a multi-dimensional health assessment questionnaire (MDHAQ) distinguishes active from control treatments in RA clinical trials as…
Abstract Number: 1105 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation to Achieve Serum Urate below 6mg/Dl: An Open Label Extension Study
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol at higher than CrCL based doses remains controversial due to concerns over increased risk of adverse events (AE). A recent 12month randomized controlled…
Abstract Number: 1106 • 2017 ACR/ARHP Annual Meeting
Association between ABCG2 rs2231142 and Poor Response to Allopurinol: Replication and Meta-Analysis
Mary Wallace¹, Rebecca Roberts², Payal Nanavati³, Jeffrey N Miner³, Nicola Dalbeth⁴, Ruth Topless⁵, Tony R. Merriman⁶ and Lisa K. Stamp⁷, ¹Surgical Sciences, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Ardea Biosciences, San Diego, CA, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁶Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁷University of Otago, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate-lowering drug. However, some patients treated with allopurinol do not achieve serum urate (SU) treatment target of <6mg/dl,…
Abstract Number: 1108 • 2017 ACR/ARHP Annual Meeting
Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load
Nicola Dalbeth¹, Jordyn de Kwant¹, Gregory Gamble², Amanda Phipps-Green³, Anne Horne², Lisa K. Stamp⁴ and Tony R. Merriman⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Increased body mass index (BMI) is an important risk factor for hyperuricemia and gout. It is unknown whether overweight and obesity influences serum urate…
Abstract Number: 1120 • 2017 ACR/ARHP Annual Meeting
Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target
Robert Morlock¹, Douglas C.A. Taylor² and Scott Baumgartner³, ¹YourCareChoice, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³drB Consulting, Spokane, WA
Background/Purpose: Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients…
Abstract Number: 1124 • 2017 ACR/ARHP Annual Meeting
Marked Variability of Circulating Urate Concentrations in Banked Samples Based on Sample Type and Assay
Evan M. Ryan¹, Michael J. Duryee², Susan K. Dover³, Elizabeth Schoenecker³, Risa Urbauer³, Flordeliza Faulkner³, Nicole Norotsky³, Harlan Sayles¹, Brian W Coburn⁴, Samuel Pirruccello¹, Geoffrey M. Thiele¹ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³U.S. Department of Veterans Affairs, Omaha, NE, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Circulating urate is an important biomarker, not only in the detection and management of gout, but also in assessing the risk of related comorbidity.…
Abstract Number: 1132 • 2017 ACR/ARHP Annual Meeting
Compensated Polarized Microscopy for Crystal Identification Shows High Reliability Among Multiple Observers
José Antonio Bernal¹, Mariano Andrés^2,3, Salvador López-Salguero⁴, Vega Jovaní⁵, Paloma Vela^3,6 and Eliseo Pascual⁷, ¹Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ²Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³Universidad Miguel Hernández, Elche, Spain, ⁴Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ⁵Reumatología, Hospital general universitario de Alicante, Alicante, Spain, ⁶Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ⁷Emeritus Professor, Universidad Miguel Hernández, Elche, Spain
Background/Purpose: The gold standard for crystal-related arthritis diagnosis remains synovial fluid analysis by a microscope fitted with compensated polarized filters as it has been shown…
Abstract Number: 1141 • 2017 ACR/ARHP Annual Meeting
Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate
Kenneth Saag¹, Mitchell Feinman², Alan J. Kivitz³, Herbert S. B. Baraf⁴, Roy Fleischmann⁵, Arthur Kavanaugh⁶ and Peter E. Lipsky⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²ACME Research, LLC, Orangeburg, SC, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁶Medicine, University of California, San Diego, La Jolla, CA, ⁷AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite initial reduction…
Abstract Number: 1372 • 2017 ACR/ARHP Annual Meeting
A Single Immunosignature Test Accurately Discriminates RA from Related Autoimmune and Inflammatory Disorders
Theodore M. Tarasow¹, Robert Gerwien¹, Jonathan Melnick¹, Scott A. Melville¹ and Chaim Putterman², ¹HealthTell, Inc., San Ramon, CA, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disease primarily targeting the synovium. RA is B-cell driven, and is associated with autoantibody production. The…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].